69 results about "Mycoplasma gallisepticum" patented technology

The invention discloses a GeXP rapid detection kit capable of simultaneously identifying nine pathogens of chicken respiratory tract diseases. The kit is used based on a GeXP system and comprises ten polymerase chain reaction (PCR) primer pairs; the kit is used for identifying and detecting avian influenza virus, H5, H7 and H9 subtype avian influenza virus, newcastle disease virus, infectious bronchitis, infectious laryngotracheitis, mycoplasma gallisepticum, bursa synovialis mycoplasma and haemophilus paragallinarum; and the kit is good in specificity, high in sensitivity and can detect 100 copy/mu l. Compared with an identifying result of the conventional experiment method of a pathogen separation and hemagglutination inhibition experiment or a serology experiment and the like, the GeXP rapid detection kit has the advantage that the coincidence rate reaches 100 percent. The kit is generally used for detecting the main chicken respiratory tract diseases and the pathogens thereof, so that a simple and high-flux detection kit and a detection system are provided, an actual requirement is met, and the application prospect is wide.

The present invention relates to a live cytadherence-deficient M. gallisepticum strain that does not express at least two of three proteins, the Gap-A molecule, crnA protein, and the 45 kDa protein, expressed by wildtype M. gallisepticum Strain R and its use as a vaccine for preventing and protecting birds, especially chickens and turkeys against the respiratory diseases attendant with wildtype Mycoplasma gallispeticum infection. The invention also relates to the use of the vaccine as a vector for the delivery of genes encoding protective antigens from other bacterial and viral avian pathogens, such as avian influenza virus. There is also disclosed a method for identifying the attenuated cytadherence-deficient M. gallisepticum Rhigh or a strain thereof.

The invention discloses a multiply-fluorescence PCR (polymerase chain reaction) detection kit for identifying strong and weak strains of mycoplasma gallisepticum. Primers used consists of a first primer, a second primer, a third primer and a fourth primer, the sequences of the first primer, the second primer, the third primer and the fourth primer in the sequence table are respectively a sequence1, a sequence 2, a sequence 4 and a sequence 5. The experiment indicates that on one hand, high amplification and excellent specificity of the PCR technology and quick sensitivity of the fluorescencedetection technology are sufficiently used in the agent and detection method; on the other hand, primer pairs universal to the strong and weak strains of the mycoplasma gallispticum and primer pairs special for weak strains and probes are assembled into a fluorescent PCR system for multiply-fluorescence PCR detection, and mutual interference is avoided, and detection sensitivity and specificity are improved further.

The invention belongs to the immunity application field, which relates to the related fields of animal molecular biochemistry and the immunology, etc. The invention discloses a reagent kit respectively used for fast testing antibody of Mycoplasma Gallisepticum Strain, which comprises a case body, and the test paper card and sample diluent equipped inside the case body, wherein, the test paper card is formed by the absorption pad, nitrocellulose membrane, gold-label pad and sample pad affixed in turn on the non-absorbent supporting flake by taking the sample pad, absorption pad and the pMGA1.2 recombinant proteins coated with the Mycoplasma Gallisepticum Strain as the detection line and the pMGA1.2 recombinant proteins coated with anti-mouse IgG as nitrocellulose membrane of the quality control line. The reagent kit used for testing the corresponding antibody has the obvious advantages of strong specificity, high sensitivity, easy operation and fast diagnosis.

The invention relates to a recombinant Newcastle disease LaSota attenuated vaccine strain expressing a mycoplasma gallisepticum TM1protein, more particularly, the recombinant Newcastle disease LaSota attenuated vaccine is rLa-tPA-TM1. The invention also discloses a method for preparing the recombinant Newcastle disease LaSota attenuated vaccine and application of the recombinant Newcastle disease LaSota attenuated vaccine in the preparation of bivalent vaccines for controlling diseases caused by mycoplasma gallisepticum and Newcastle disease.

The invention provides a preparation method of a chicken infectious rhinitis lipid inactivated vaccine, belonging to the technical field of biological products for animals. The preparation method is implemented by the following steps of: preparing a type A haemophilus paragallinarum inactivated antigen bacterial liquid and a type C haemophilus paragallinarum inactivated antigen bacterial liquid; uniformly mixing the type A haemophilus paragallinarum inactivated antigen bacterial liquid with the type C haemophilus paragallinarum inactivated antigen bacterial liquid in the volume ratio of 1:1, and pouring into an emulsifying tank; stirring with a mixer; slowly adding poplar bark lipid at a low speed till the final volume percentage concentration of the poplar bark lipid in the mixture is 2.0-3.8 percent; and continually stirring and emulsifying for 30-60 minutes to obtain the vaccine, wherein the final bacterium content of a type A strain and the final bacterium content of a type C strain in the vaccine are 1,000,000,000 cfu/ml. The vaccine has the advantages of easiness for absorbing, no toxic or side effect, short immunogenic time, long immune duration, good immune effect and capability of effectively preventing chicken infectious rhinitis and mycoplasma gallisepticum.

The invention discloses an LAMP assay kit for identifying virulent and avirulent strains of mycoplasma gallisepticum. A primer group A provided by the LAMP assay kit consists of a primer group a and a primer group b; the primer group a consists of a primer 1 and a primer 2; the primer group b consists of a primer 3 and a primer 4; and the nucleotide sequences of the primer 1, the primer 2, the primer 3 and the primer 4 are sequence 1, sequence 2, sequence 3 and sequence 4 sequentially in a sequence table. An experiment for the LAMP assay kit proves that the primers and the method only need anordinary water bath rather other an expensive PCR (Polymerase Chain Reaction) instrument but have higher sensitivity than PCR assay, moreover, a result does not need to be observed by way of gel electrophoresis, and the LAMP assay kit is easy and rapid to operate, and is particularly suitable for field assay in grass roots.

The invention discloses a preparation method of a recombinant antimicrobial peptide extracted from a small intestine of a pig and an application thereof. The preparation method comprises the following steps: mashing, homogenizing and repeatedly freezing and thawing the small intestine tissue of the pig with a meat grinder and a colloid mill, and preliminarily crushing cells; then performing the water boiling heat treatment, and extracting with acetic acid solution to obtain a large amount of antimicrobial peptides; centrifuging to enable the quantity of other proteins to be reduced greatly, filtering the supernate obtained through centrifuging by a tangential flow micro-filtration membrane and a tangential flow ultrafiltration membrane sequentially, adjusting the pH value, filtering the supernate by a tangential flow nanofiltration membrane, concentrating and dialyzing to desalt, and disinfecting after adjusting the osmotic pressure to obtain the recombinant antimicrobial peptide extracted from the small intestine of the pig. According to the invention, the application of the recombinant antimicrobial peptide adopts effects of the antimicrobial peptide on aspects of mucosal immunity, immunopotentiators, novel antibiotics and the like, and the mucosal immunity character of the antimicrobial peptide can play an important role in the prevention and control of transmissible gastroenteristis, epidemic diarrhea and mycoplasma gallisepticum; the antimicrobial peptide replaces traditional antibiotics, and is remarkable in effect.

The present invention provides a protective formulation that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes. The formulation comprises a protective amount of live MG strain K5054 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma gallisepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

The invention provides a lincomycin hydrochloride-spectinomycin sulfate injection and a preparation method thereof. Water for injection is taken as a carrier; and 100ml of injection contains 3 to 7g of lincomycin hydrochloride and 8 to 12g of spectinomycin sulfate. The invention has the advantages that the injection is safe and reliable, and has low toxic or side effect and high bioavailability; lincomycin hydrochloride-spectinomycin sulfate is prepared into a compound hydro-acupuncture injection, the injection has a synergistic effect and a relatively wide antibacterial spectrum, can remarkably strengthen the antibacterial activity on mycoplasmas, can act quickly, and has low toxicity, and the therapeutic dose of the injection does not have adverse affect on chickens and pigs; and the injection has a good effect of treating respiratory diseases of livestock, particularly mycoplasmal pneumonia, digestive tract diseases of the livestock, and chicken chronic respiratory diseases which are caused by mycoplasma gallisepticums, is favorable for reducing the medicine tolerance of medicines, and prolongs the service life of the medicines.

The present invention provides a formulation that prevents virulent Mycoplasma galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live Mycoplasma galHsepticum strain K5831 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma galHsepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

The invention discloses a drug resistance judgment standard test method of mycoplasma gallisepticum to danofloxacin, including the following steps: formulating a wild type critical value and a pharmacodynamic critical value of the danofloxacin to the mycoplasma gallisepticum, formulating a dosing scheme of the danofloxacin to the mycoplasma gallisepticum, formulating a clinical critical value of the danofloxacin to the mycoplasma gallisepticum, and obtaining a drug resistance judgment standard of the danofloxacin to the mycoplasma gallisepticum through a tree diagram which is made through a CLSI susceptibility breakpoint. With the adoption of the drug resistance judgment standard test method of mycoplasma gallisepticum to danofloxacin, the drug resistance judgment standard of the mycoplasma gallisepticum to the danofloxacin can be formulated; stable medication data support can be provided for scientific cultivation; clinical medication can be guided more scientifically; chronic respiratory diseases such as nasosinusitis, trachitis and air sacculitis of chickens can be effectively treated; reference is provided for clinical medication; drug resistance of mycoplasma gallisepticum todanofloxacin can be effectively relieved to a certain extent; and effectiveness of danofloxacin is protected and maintained.

The present invention discloses a medicine which is used for preventing and treating mycoplasma gallisepticum. The medicine comprises the ingredients of the following weight portions: 5 to 15 portions of dyer woad root, 5 to 15 portions of cordate houttuynia, 5 to 15 portions of dyer woad leaf, 5 to 15 portions of honeysuckle, 5 to 15 portions of radix scutellariae, 5 to 15 portions of forsythia, 3 to 10 portions of Chinese ephedra, 3 to 10 portions of almond, 3 to 10 portions of balloon-flower root, 10 to 30 portions of plaster, 3 to 10 portions of rhizoma anemarrhenae, 2 to 6 portions of fried draba nemorosa linnei, 2 to 6 portions of fried perilla, 2 to 6 portions of white fructus tribuli, 2 to 6 portions of chrysanthemum, 2 to 6 portions of rhubarb, 2 to 6 portions of gardenia, 2 to 6 portions of powder of gall bladder, and 2 to 6 portions of licorice. The herbs are insolated, weighed, crushed, filtered by a sieve with 60 to 80 meshes, and mixed well, so as to prepare the medicine. When in clinical use, the medicine is dipped for 30 to 60 minutes in boiling water, so that the effective ingredients can be fully dissolved and separated to facilitate the absorption in the body of the sick chicken. Simultaneously, a small amount of sugar and Vc are added to improve the medicinal effects. The medicine has high cure rate, no adverse reaction, no drug residues in the body, and nearly no drug resistance. The production of the medicine has the advantages of easily available raw materials, simple preparation, convenient use, and capability of wide promotion and application in the chicken breeding industry.

The invention relates to a new usage of citric acid and compound citric acid in the field of pharmacy. The product can prevent and control viral diseases and bacterial diseases of livestock and poultry; wherein, the compound citric acid comprises the following components according to weight portion: 93-98 portions of citric acid, 0.5-4 portions of gualfenesin and 1.5-3 portions of etamsylate. Proved by in vivo and vitro experiments, the compound citric acid can play a role in preventing and controlling fowl mycoplasma gallisepticum, avian influenza (H9 subtype), bursal virus disease and other diseases, and can effectively kill animal pathogenic bacterias such as cattle colon bacillus, mycoplasma gallisepticum, chicken colibacillosis, etc.

The invention provides a multiplex PCR detection primer set and kit used for mycoplasma gallisepticum, mycoplasma gallisepticum and parabacterium bacillus and application of the kit, and belongs to the technical field of molecular detection. The primer set comprises MS-F, MS-R, MG-F, MG-R, APG-F and APG-R; the nucleotide sequences of MG-F, MG-R, MS-F, MS-R, APG-F and APG-R are shown in SEQ ID NO:1-SEQ ID NO:6 respectively. It is verified that the primer set has high specificity and sensitivity.

The invention discloses a fluid culture medium. The fluid culture medium is prepared by mixing a basic culture medium and an auxiliary culture medium. The basic culture medium contains the following components by mass concentration (g/L): 3-7 g/L of sodium chloride, 0.3-0.6 g/L of potassium chloride, 1.5-3.5 g/L of sodium phosphate dibasic dodecahydrate, 0.1-0.4 g/L of magnesium sulfate heptahydrate, 0.1-0.2 g/L of potassium dihydrogen phosphate, 10-15 g/L of glucose, 6-8 g/L of lactoalbumin hydrolysate and 6-7 g/L of yeast extract powder; and the auxiliary culture medium contains the following components by volume concentration (mL/L): 40-80 mL/L of fetal calf serum, 1-2 mL/L of penicillin, 2-3 mL/L of phenol red, 40-80 mL/L of a DMEM high glucose culture medium, 8-10 mL/L of arginine, 8-10 mL/L of cysteine and 8-10 mL/L of coenzyme I. The invention further discloses a preparation method for the culture medium and a method for isolated-culturing mycoplasma gallisepticum using the culture medium. The fluid culture medium is capable of providing the more excellent growing conditions, accelerating metabolism, advantageously shortening isolation time of the mycoplasma gallisepticum and improving an isolating rate.

The invention discloses a new application of p-hydroxyl cinnamic acid in preparing a medicament for preventing and curing viral diseases or bacterial diseases of livestock and poultries. The product can prevent and cure viral and bacterial diseases of the livestock and the poultries and improve the production performance of the livestock and the poultries. Proved by in vivo and in vitro experiments, the p-hydroxyl cinnamic acid has the effects of preventing and curing diseases caused by mycoplasma gallisepticums, cow escherichia coli, and the like. Proved by in vivo experiments, the p-hydroxyl cinnamic acid has the effects of preventing and curing Fabricius bursal viral diseases of the livestock and the poultries, avian mycoplasmosis and avian influenza H9 and H5 subtype virus infections.

The invention discloses pleuromutilin compounds with thioether side chains as well as a preparation method and an application of the pleuromutilin compounds and belongs to the field of medicinal chemistry. The compounds have the structure shown in the formula 2 or in the formula 3, wherein R1, R2 and R3 are independently selected from hydrogen, methoxyl, methyl, hydroxy, nitryl, halogen and trichloromethyl; R is ethyl or vinyl. The pleuromutilin compounds with the thioether side chains have good activity for inhibiting mycoplasma gallisepticum and are particularly suitable for being taken as a novel antimycoplasma drug to be used for preventing and treating mycoplasma infection diseases of human beings or animals.

The invention discloses new application of p-hydroxycinnamic acid to preparation of medicines for preventing and treating viral disease or bacterial disease of livestock and poultry. The product can prevent and treat viral disease or bacterial disease of livestock and poultry and can improve production performance of livestock and poultry. In vivo and in vitro tests show that the p-hydroxycinnamic acid can prevent and treat diseases caused by mycoplasma gallisepticum, bovine colibacillosis and the like. The in vivo test shows that the p-hydroxycinnamic acid can prevent and treat poultry bursafabricius viral disease, avian mycoplasmosis and bird flu H9 and H5 subtype virus infection.

The invention provides lactobacillus plantarum and a microecological preparation, a preparation method and application thereof. The lactobacillus plantarum is named as Lactobacillus Plantarum BLCC2-0125, and is preserved in the China Center for Type Culture Collection in Wuhan City on April 24th, 2020, and the preservation number is CCTCC NO: M 2020078. The lactobacillus plantarum can improve thebody immunity, has a prevention effect on low-pathogenicity avian influenza, and can prevent and treat mycoplasma gallisepticum disease.